BullsEye Insights

BullsEye: Daily London AIM RNS Round-Up

Thursday 21 May 2020


Here is our summary of the day's hottest RNS alerts from across London's Alternative Investments Market (AIM).


Beximco Pharmaceuticals (BXP.LSE)

World's first generic remdesivir for COVID-19

Beximco Pharmaceuticals Limited, the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announced the launch of remdesivir (under the brand name Bemsivir), an antiviral drug, which has been recently granted Emergency Use Authorization by the U.S. Food and Drug Administration for the treatment of COVID-19. With this introduction, Beximco Pharma is the first company in the world to launch a generic version of remdesivir for the treatment of COVID-19.

The launch, which was anticipated in the Company's announcement on 4 May 2020, follows the grant of Emergency Use Authorisation by the Directorate General of Drug Administration (DGDA), the regulatory authority in Bangladesh, for Beximco Pharma's remdesivir IV injection (under the brand name Bemsivir) received on 21 May 2020. Emergency approvals will help to broaden the use of remdesivir in hospitalised patients, especially in developing and least developed countries where access to breakthrough, advanced drugs remains a major challenge.

Originally developed by Gilead Sciences, Inc., remdesivir is a direct acting antiviral drug that inhibits viral RNA synthesis. Remdesivir is administered intravenously and is authorised for the treatment of hospitalised patients with severe COVID-19 disease. Recent clinical trials have shown evidence that remdesivir helps severe COVID-19 patients recover faster.

Beximco Pharma is donating remdesivir (Bemsivir) to the Bangladesh Government for supply only to Government hospitals free of charge. Remdesivir (Bemsivir) will not be available through retail pharmacies, in compliance with the directives from the DGDA.


For the full RNS, see: https://www.investegate.co.uk/beximco-pharmaceut--bxp-/rns/world-s-first-generic-remdesivir-for-covid-19/202005210700075467N/

Salt Lake Potash Limited (SO4.LSE)

Lake Way Paleochannel Bore Pumping Results

Salt Lake Potash Limited (SO4 or the Company) is pleased to announce positive results from the pumping of its paleochannel brine extraction bore at Lake Way.

  • Pumping of the initial brine extraction bore drilled into the Lake Way paleochannel delivered flow rates of 18 litres per second with a consistent Potassium grade of 7,100mg per litre (15.9kg/m3 SOP), sustained over a 17 day period.

  • The results are significantly above average flow rates used in the Bankable Feasibility Study (BFS) announced 11 October 2019 of 8.4 litres per second (per bore) and average interpolated brine grades within the paleochannel of 6,100mg per litre (13.7kg/m3 SOP).

  • Drawdown of brine observed in monitoring bores located next to the pumping bore aligned with hydrogeological assumptions used in the BFS. 

  • The response to pumping observed in a monitoring bore 1.6 km away indicates continuity of the aquifer, whilst brine samples also indicate a consistent grade within this zone of the paleochannel.

  • Two additional brine extraction bores have been completed along the paleochannel with pumping expected to commence in the near term. In each case the primary basal sand aquifer was encountered in line with our geological model prediction.

"Strong results from pumping our first brine abstraction bore validates work undertaken as part of the BFS and highlights the value of the paleochannel resource which will be a significant contributor of brine supply to our ponds over the life of the project."

In April SO4 commenced drilling its first brine extraction bore into the paleochannel basal sands at Lake Way.

The bore was located at Pad 17 with two monitoring bores also drilled adjacent. Test pumping was sustained over a 17 day period.


During the test pumping, brine samples were taken every 24 hours. Potassium and Sulphate grades were consistent throughout, averaging 7,100mg per litre and 29,700mg per litre respectively (15.9kg/m3 SOP) . The 17 day duration of the test and constant pumping rate of 18 litres per second  was sufficient to stress the aquifer and to model the longterm aquifer response to pumping.


Brine levels were measured in all three bores at Pad 17 and also in a monitoring bore at Pad 21 approximately 1.6km to the North.


Drawdown observed in the monitoring bores located at Pad 17 demonstrated that brine flow is sourced from lateral flow within the basal sand aquifer as well as from downward vertical leakage from the overlying paleovalley clays. This is consistent with modelling assumptions set out in the BFS.


Furthermore, drawdown was observed in the monitoring bore at Pad 21, indicating a strong continuity of flow and grade within this zone of the paleochannel. A brine sample taken from the monitoring bore at Pad 21 reported a grade of 7,230mg per litre Potassium (16.2kg/m3) and 29,500 mg per litre Sulphate, consistent with that seen at Pad 17.


In the months ahead SO4 will drill and test pump further brine extraction bores along the Eastern side of Lake Way. During May bores have been completed at Pads 8 and 21, with test pumping expected to be completed in the near term.  In each case the primary basal sand aquifer was encountered in line with our geological model prediction.


For full RNS details, see: https://www.investegate.co.uk/salt-lake-potash-ltd--so4-/rns/lake-way-paleochannel-bore-pumping-results/202005210830046028N/

Feedback Plc (FDBK.LSE)

Papworth NHS Hospital - contract renewal with Bleepa

Feedback plc, the specialist medical imaging technology company, today announced Royal Papworth Hospital NHS Foundation Trust has renewed its contract for clinical PACS (picture archiving and communication system) services with Feedback Medical Ltd, a wholly owned subsidiary of the Company.  The renewal will incorporate an upgrade to service, providing the Trust access to Bleepa®, Feedback's flagship imaging-based communication platform.

The contract, set for a term of 14 months, rel ates to Feedback's Cadran PACS which has provided core medical imaging services to the Trust since 2001. The contract includes the use of Bleepa® as an upgrade to Cadran Web Viewer and will see Bleepa® made available to all clinicians at the Trust.

Royal Papworth Hospital is the UK's leading heart and lung hospital, treating more than 100,000 patients each year.  Since carrying out the UK's first successful heart transplant in 1979, the hospital now performs more heart, heart-lung and lung transplants each year than any other UK centre.  In addition to transplantation, Royal Papworth Hospital has the UK's largest Respiratory Support and is one of five UK centres providing Extra Corporeal Membrane Oxygenation (ECMO) to patients experiencing severe respiratory failure.

For Feedback, the contract marks the second NHS site to adopt Bleepa® as a core imaging tool and is further recognition of the potential that Bleepa® has to enhance clinical care delivery. The first site was the Pennine Acute NHS Hospitals Trust which is using Bleepa® to support frontline staff to manage Covid-19 patients.

Tom Oakley, CEO of Feedback plc, said:


"Papworth has been a longstanding customer of Feedback and we are delighted that they recognise the value of Bleepa ® as part of this renewal. Enabling critical review at the push of a button, Bleepa ® has the functionality to bring significant efficiencies and deliver real time-saving potential for its clinicians. The launch of Bleepa at Papworth is further evidence of the changing needs of frontline clinicians around their interaction with medical imaging and with colleagues, something that we are uniquely positioned to enable. We will now look to continue the spread of Bleepa to other opportunities across the healthcare setting."

Bleepa® provides instant and remote access to clinical grade medical images through a zero footprint application.  The majority of patient cases require medical imaging which can be seamlessly shared to the entire clinical team through Bleepa ® .  Cases can be discussed through its secure instant messaging and image annotation, allowing comments and treatment decisions to be communicated instantly between team members.  Bleepa ® can be accessed from any internet connected device including phones, tablets, laptops and desktops; clinicians can use their own devices and therefore no additional hardware is required.


For full RNS details, see: https://www.investegate.co.uk/feedback-plc/rns/papworth-nhs-hosp---contract-renewal-with-bleepa/202005210700085474N/

Download the BullsEye app for your phone or tablet

AppStore.png
playstore.png

*tap here*